Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SKI3246 is a standardized oral extract of the rhizome of Atractylodes japonica, a perennial plant native to North Asia. It is being developed as a small molecule drug for the treatment of digestive system disorders, particularly irritable bowel syndrome with diarrhea (IBS-D). Preclinical studies indicate that SKI3246 can increase colonic transit time in vitro and may modulate lower gastrointestinal motility, although its effects in vivo are less pronounced. In animal models, it has shown potential to decrease fecal output under certain conditions and attenuate visceral pain responses. The mechanism of action remains unknown but is presumed to involve modulation of gastrointestinal motility and possibly anti-inflammatory or neuromodulatory pathways. Clinical trials have evaluated its efficacy and safety in patients with non-constipation irritable bowel syndrome.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atractylodes japonica extract.